News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
55 Results
Section
Business (16)
Deals (2)
Drug Development (13)
News (29)
Tag
Alliances (2)
Clinical research (6)
Earnings (10)
Events (5)
IPO (2)
People (3)
Phase I (4)
Phase II (3)
Preclinical (6)
Startups (1)
Date
Last 7 days (1)
Last 30 days (2)
Last 365 days (17)
2025 (2)
2024 (20)
2023 (2)
2022 (1)
2021 (2)
2020 (1)
2019 (1)
2016 (18)
2015 (4)
2014 (3)
2013 (1)
55 Results for "cantargia".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Cantargia Publishes Interim Report for the First Quarter of 2024
Cantargia Cantargia announced its interim report for the first quarter of 2024.
May 21, 2024
·
3 min read
Business
Cantargia Publishes Annual Report for 2023
Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that the annual report for 2023 has been published.
April 18, 2024
·
1 min read
Drug Development
Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10
Cantargia Cantargia reported progress in the ongoing phase 1 clinical trial of the CAN10 antibody. Seven dose groups have now been concluded without any safety concerns.
June 14, 2024
·
4 min read
Cantargia ASCO Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy
Cantargia Cantargia gave a presentation at the ASCO conference showing clinical data on nadunolimab counteracting the serious problem of chemotherapy induced neuropathy, an additional positive finding beyond its promising antitumor effects.
June 1, 2024
·
4 min read
Business
Cantargia Strengthen Management Team with The Appointment of Ton Berkien as Chief Business Officer
Cantargia, announced the strengthening of its management team through the recruitment of Ton Berkien as Chief Business Officer.
June 11, 2024
·
2 min read
Cantargia presents unique effects of nadunolimab in pancreatic cancer
Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented new preclinical data for its lead candidate, the IL1RAP-binding antibody nadunolimab (CAN04) at the AACR Annual Meeting.
April 8, 2024
·
4 min read
Annual General Meeting in Cantargia AB (publ) - May 23, 2024
Cantargia’s Annual General Meeting on 23 May 2024 resolved in accordance with the following.
May 23, 2024
·
3 min read
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis
Cantargia Cantargia reported publication of promising preclinical data supporting the potential of the anti-IL1RAP antibody CAN10 as treatment of atherosclerosis.
April 2, 2024
·
4 min read
Business
Cantargia Publishes Year-End Report for 2023
Cantargia Cantargia announced its interim report for the fourth quarter and year-end 2023.
February 22, 2024
·
3 min read
Business
Invitation to Presentation of Cantargia’s Interim Report for Q1 2024 on May 21 at 3.00 p.m. CEST
Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) will publish the company’s interim report for the first quarter 2024 on Tuesday, May 21, 2024, at 07:00 a.m. CEST.
May 7, 2024
·
2 min read
1 of 6
Next
